EMCDDA Home
  • EN
Search

Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances

EMCDDA, Lisbon, May 2014

Publication type:

Risk assessments

Summary:

This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this issociative drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

Download as pdf (354Kb):

English (en)

Table of contents

  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on methoxetamine: a summary
  • Risk Assessment Report of a new psychoactive substance: methoxetamine
  • Annex 1: Technical report on methoxetamine
  • Council Implementing Decision of 25 September 2014 on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures
  • Participants of the risk assessment meeting

Pages:

26

Price:

free

ISBN/ISSN:

978-92-9168-747-3

Catalogue number:

TDAK14004ENN

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00

More contact options >>

Page last updated: Wednesday, 08 October 2014